MLTX SHAREHOLDER ALERT: BFA Law Notifies MoonLake Immunotherapeutics Investors of Important December 15 Securities Class Action Deadline for Investors seeking Recovery

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, with a deadline for investors to seek recovery by December 15, 2025 [2][4]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa (HS) [5]. Group 2: Allegations and Clinical Data - The lawsuit alleges that MoonLake misrepresented its clinical data, claiming that its "strong clinical data" would lead to superior clinical responses compared to competitors [6]. - It is claimed that the Nanobody structure of SLK did not provide a clinical benefit over traditional monoclonal antibody treatments, raising doubts about the drug's regulatory approval and commercial viability [7]. Group 3: Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [8].